Clinical Trials on Gingivitis, Necrotizing Ulcerative in Hungary

Total 142 results

Lycera Corp.

Completed

Safety and Pharmacokinetic Study of LYC-30937 in Subjects With Active Ulcerative Colitis

Ulcerative Colitis

Hungary
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis

Ulcerative Colitis

Poland, Bulgaria, Hungary
Abivax S.A.

Active, not recruiting

Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis

Belgium, Poland, Czechia, Hungary
Novo Nordisk A/S

Terminated

A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis

Inflammation | Ulcerative Colitis

Poland, Croatia, Denmark, Bulgaria, Hungary, Ukraine, Russian Federation
Hoffmann-La Roche

Terminated

Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)

Ulcerative Colitis

United States, Hungary, Georgia, Moldova, Republic of, Ukraine
Novartis Pharmaceuticals

Terminated

Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients

Ulcerative Colitis

Belgium, Hungary, Switzerland, Germany, Sweden, United Kingdom
Palau Pharma S.A.

Completed

A Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

Belgium, Hungary, Slovakia, Spain
Avaxia Biologics, Incorporated

Completed

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

Ulcerative Colitis

United States, Hungary, Belgium, Canada
Geert D'Haens
Takeda

Completed

An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis (LOVE-UC)

Colitis, Ulcerative

Netherlands, Belgium, Hungary
Ferring Pharmaceuticals

Completed

Study to Assess Effectiveness of Therapy Timely Adjustment Based on Self-monitoring in Patients Suffering From Mild-to-moderate Ulcerative Colitis (OPTIMISE Study) (OPTIMISE)

Mild-to-moderate Ulcerative Colitis

Poland, Hungary, Italy, Czechia, Netherlands, Slovakia
Topivert Pharma Ltd

Completed

Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis (TOP2)

Ulcerative Colitis

Poland, Ukraine, United Kingdom, Bulgaria, Hungary, Lithuania, Czechia, Latvia
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

Ulcerative Colitis

United States, Georgia, Germany, Hungary, Moldova, Republic of, Poland, Ukraine, United Kingdom
Sanofi

Completed

Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study (NICE)

Ulcerative Colitis | Inflammatory Bowel Disease

Canada, Brazil, Russian Federation, Italy, Spain, Sweden, Estonia, Singapore, Belgium, Czech Republic, Argentina, Hungary, Chile, South Africa
Galapagos NV

Completed

Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis (ORIGIN)

Ulcerative Colitis

Belgium, Czech Republic, Germany, Hungary, Poland, Russian Federation
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis

United States, Belgium, Netherlands, Canada, Hungary, Moldova, Republic of, Romania
Biogen

Completed

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Active Ulcerative Colitis

United States, Canada, Czech Republic, Hungary, Poland, Russian Federation, Slovakia
Shire

Completed

Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis (PACE)

Ulcerative Colitis

United States, United Kingdom, Israel, Canada, Hungary, Poland, Slovakia
Infant Bacterial Therapeutics

Active, not recruiting

IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

Necrotizing Enterocolitis

United States, Spain, Israel, United Kingdom, France, Poland, Romania, Bulgaria, Hungary, Serbia
AbbVie

Completed

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

Ulcerative Colitis (UC)

United States, Canada, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Spain, United Kingdom
Amgen

Recruiting

Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Germany, Japan, Denmark, Romania, Argentina, Bulgaria, Hungary, Korea, Republic of, Mexico, Poland, Switzerland, Turkey
Celgene

Active, not recruiting

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Germany, Greece, United Kingdom, Hungary, Belgium, Slovakia, Bulgaria, Italy, Australia, Israel, Belarus, Romania, Ukraine
sigma-tau i.f.r. S.p.A.
PRA Health Sciences

Terminated

Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study

Ulcerative Colitis

Poland, Hungary, Austria, France, Germany, Latvia, Lithuania, Spain
OSE Immunotherapeutics

Recruiting

Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis (CoTikiS)

Ulcerative Colitis

Belgium, Latvia, Bulgaria, Belarus, Croatia, Georgia, Hungary, Poland, Russian Federation, South Africa, Ukraine
Protagonist Therapeutics, Inc.

Completed

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Severe

United States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
Facet Biotech
PDL BioPharma, Inc.

Terminated

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

Ulcerative Colitis

Belgium, France, United States, Italy, Canada, Czech Republic, Norway, Israel, Austria, Croatia, Australia, Hungary, Ukraine, Netherlands, Germany
InDex Pharmaceuticals

Completed

The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis (CONDUCT)

Ulcerative Colitis

Hungary, Czechia, France, Germany, Poland, Russian Federation, Serbia, Spain, Sweden, Ukraine
Genentech, Inc.

Completed

Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Israel, Belgium, Australia, Czechia, New Zealand, Canada, Spain, Germany, United Kingdom, Hungary
Bristol-Myers Squibb

Completed

A Study of MDX-1100 in Subjects With Active Ulcerative Colitis (MDX1100-06)

Ulcerative Colitis

Ukraine, United States, Romania, Russian Federation, Czech Republic, Hungary, Canada, Latvia
Vedanta Biosciences, Inc.

Recruiting

VE202 in Patients With Mild-to-Moderate Ulcerative Colitis

Ulcerative Colitis | Colitis, Ulcerative

United States, Netherlands, Lithuania, Bulgaria, Hungary, Ukraine, Czechia, Poland, United Kingdom
Galapagos NV

Terminated

A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission (CAPYBARA)

Ulcerative Colitis

United States, Germany, Korea, Republic of, Spain, France, Hungary, United Kingdom, Poland, Belgium, Czechia, Italy, South Africa, Taiwan
InDex Pharmaceuticals

Completed

The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients (COLLECT)

Colitis, Ulcerative

Czechia, France, Germany, Hungary, Italy, Poland, United Kingdom
PPM Services S.A.

Terminated

Efficacy and Safety Study of GED-0507-34-Levo for Treatment of UC (SEGMENT)

Ulcerative Colitis

United States, Hungary, Slovakia, Italy, Ukraine, Bulgaria, Poland, Latvia, Canada, France
Kyowa Kirin, Inc.

Completed

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

Digestive System Diseases | Gastrointestinal Diseases | Colonic Diseases | Intestinal Diseases | Abdominal Pain | Inflammatory Bowel Diseases | Ulcerative Colitis | Colitis | Colitis, Ulcerative | Autoimmune Disease

Hungary, Russian Federation, Serbia, United States, Poland, Czechia, Romania
PDL BioPharma, Inc.

Terminated

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

Ulcerative Colitis

Belgium, France, United States, Italy, Australia, Czech Republic, Netherlands, Ireland, Norway, Canada, Austria, Germany, Hungary, Ukraine
Takeda
Takeda Development Center Americas, Inc.

Active, not recruiting

Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Crohn's Disease | Ulcerative Colitis

Israel, United States, Hungary, Belgium, France, Poland, Ukraine, United Kingdom
Genentech, Inc.

Completed

Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

Belgium, Spain, New Zealand, United States, Czech Republic, Germany, Australia, United Kingdom, Israel, Hungary, Canada
Eli Lilly and Company

Recruiting

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-URGE)

Ulcerative Colitis | Ulcerative Colitis Chronic

United Kingdom, United States, Poland, Czechia, Hungary, Italy, France, Slovakia, Germany, Belgium
Applied Molecular Transport

Active, not recruiting

Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)

Ulcerative Colitis

United States, Hungary, Ukraine, Germany, United Kingdom, Belarus, Bulgaria, Canada, France, Georgia, Moldova, Republic of, Poland, Russian Federation, Switzerland
Ferring Pharmaceuticals

Completed

Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)

Ulcerative Colitis

Switzerland, Russian Federation, Latvia, United States, Hungary, Ukraine, Serbia, Bulgaria, Canada, Mexico, Poland
Pfizer

Completed

A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.

Ulcerative Colitis

Brazil, Hungary, Belgium, Czech Republic, Italy, South Africa, Spain, United Kingdom, Sweden, Slovakia, Denmark, Poland, France, Chile, Israel, Mexico, Netherlands
Bristol-Myers Squibb

Completed

A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

Crohn Disease | Ulcerative Colitis

Romania, Italy, United States, Australia, Canada, China, Germany, Hungary, Japan, Netherlands, Poland, Portugal, Russian Federation, Spain, Taiwan, United Kingdom
Takeda

Completed

An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease (GEMINI LTS)

Crohn's Disease | Ulcerative Colitis

Belgium, United States, Korea, Republic of, Malaysia, Canada, Israel, Australia, Hungary, Czechia, Germany
AbbVie

Completed

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Australia, Austria, Belgium, Canada, Czechia, Hungary, Israel, Japan, New Zealand, Poland, Slovakia, Spain, United Kingdom
Hoffmann-La Roche
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis

United States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
Gilead Sciences

Recruiting

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis (PALEKONA)

Ulcerative Colitis

United States, Australia, United Kingdom, Korea, Republic of, Japan, Italy, France, Canada, Switzerland, Austria, Germany, Hungary, Poland
Ferring Pharmaceuticals

Completed

Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)

Ulcerative Colitis

Switzerland, Russian Federation, Latvia, United States, Hungary, Ukraine, Bulgaria, Canada, Mexico, Poland, Serbia
Hoffmann-La Roche

Completed

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (HIBISCUS II)

Ulcerative Colitis

Australia, Czechia, France, Russian Federation, Malaysia, Bulgaria, United States, Croatia, Poland, Ukraine, Hungary, Colombia, New Zealand, Argentina, Turkey, Latvia, Brazil, Lithuania, Greece
Theravance Biopharma

Terminated

Efficacy & Safety of TD-1473 in Ulcerative Colitis (RHEA)

Ulcerative Colitis (UC)

United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
AbbVie

Completed

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, Romania, Slovakia, Spain, Switzerland, Ukraine, United Kingdom
Sanofi

Recruiting

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis (RESOLUTE)

Colitis Ulcerative

Argentina, Chile, United States, China, Czechia, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Spain, United Kingdom

Clinical Trials on Gingivitis, Necrotizing Ulcerative in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations